Abstract 31P
Background
Cervical cancer is a major public health concern as it is the fourth leading cause of cancer-related fatalities among women. India has the highest incidence of cervical cancer worldwide. Omics diagnostic tools, particularly proteomics, are helpful in tracking the development of the disease as cancer therapy continues to shift towards precision medicine. The primary objective of this study was to explore the global protein expression patterns of cervical cancer in the Indian population for the first time to encourage the application of current diagnostic and treatment modalities.
Methods
We employed MS-based quantitative global (Label-free quantification or LFQ) and targeted proteomics (multiple reaction monitoring or MRM) in bio-banked tissue samples of cervical cancer and healthy tissue (Control=8, Tumor=7; 6 Paired, 2 unpaired). With a very small amount of starting tissue material (10-12 mg) proteomic biomarker profiling was conducted as pilot research. Finally, a complex set of protein candidates belonging to the mRNA splicing and MTORC1 signaling pathway has been confirmed and refined at the peptide level by MRM assay.
Results
We observed proteins belonging to the mRNA processing and maturation via alternative splicing pathway were overexpressed in cervical tumors. Heterogeneous nuclear ribonucleoproteins (hnRNPs), the components of spliceosome complex regulate both constitutive and alternative splicing in tumors. We found at least 5 hnRNPs and few HSP (heat-shock proteins) to be significantly overexpressed in tumors via global proteomics. Validation of candidate hnRNPs (HNRNPA2, HNRNPA1) and Heat-shock proteins (HSPs) were done by targeted proteomics. Furthermore, we developed a comprehensive panel of peptides which can be investigated to check for the effectiveness of tumour development which pave the way towards a better diagnosis.
Conclusions
This foundation study, for the very first time, facilitated the development of a panel of proteomic biomarkers of Cervical cancer in Indian population. We propose that a set of these markers including HNRNPs can be further useful for the development of a complete biomarker panel for cervical cancer diagnosis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Indian Institute of Technology, Bombay.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
42P - Investigating the influence of extrachromosomal DNA in the progression of non-small cell lung cancer through the TRACERx and PEACE studies
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
Presenter: Diego Gomez Puerto
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Exploring miR-205 and miR-296 as salivary biomarkers and potential therapeutic targets in oral cancer
Presenter: Thaís Moré Milan
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence
Presenter: Jinhwa Hong
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Differential expression of discriminative markers in matched invasion fronts and tumour buds in CRC
Presenter: Laura Grech
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Transcriptome profiling highlights distinct gene signatures in HER2 high (HER2 3+) and HER 2 low (Her2 1+/2+) breast cancers
Presenter: Tamanna Thakur
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - MiR-155 promotes breast cancer progression by upregulating cancer stemness
Presenter: Jeonghee Han
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study
Presenter: Christophe Mapendano
Session: Cocktail & Poster Display session
Resources:
Abstract
51P - Functional characterization of the novel long intergenic non-coding RNA-RFC4, a transcript regulating chromosomal instability in prostate cancer
Presenter: Rogelio Montiel Manríquez
Session: Cocktail & Poster Display session
Resources:
Abstract